Overexpression of Inosine 5'-monophosphate Dehydrogenase Type II Mediates Chemoresistance to Human Osteosarcoma Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Sep 3

PMID 20808934

Citations 24

Authors

Jorg Fellenberg

Pierre Kunz

Heiner Sahr

Daniela Depeweg

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance is the principal reason for poor survival and disease recurrence in osteosarcoma patients. Inosine 5'-monophosphate dehydrogenase type II (IMPDH2) encodes the rate-limiting enzyme in the de novo guanine nucleotide biosynthesis and has been linked to cell growth, differentiation, and malignant transformation. In a previous study we identified IMPDH2 as an independent prognostic factor and observed frequent IMPDH2 overexpression in osteosarcoma patients with poor response to chemotherapy. The aim of this study was to provide evidence for direct involvement of IMPDH2 in the development of chemoresistance.

Methodology/principal Findings: Stable cell lines overexpressing IMPDH2 and IMPDH2 knock-down cells were generated using the osteosarcoma cell line Saos-2 as parental cell line. Chemosensitivity, proliferation, and the expression of apoptosis-related proteins were analyzed by flow cytometry, WST-1-assay, and western blot analysis. Overexpression of IMPDH2 in Saos-2 cells induced strong chemoresistance against cisplatin and methotrexate. The observed chemoresistance was mediated at least in part by increased expression of the anti-apoptotic proteins Bcl-2, Mcl-1, and XIAP, reduced activation of caspase-9, and, consequently, reduced cleavage of the caspase substrate PARP. Pharmacological inhibition of IMPDH induced a moderate reduction of cell viability and a strong decrease of cell proliferation, but no increase in chemosensitivity. However, chemoresistant IMPDH2-overexpressing cells could be resensitized by RNA interference-mediated downregulation of IMPDH2.

Conclusions: IMPDH2 is directly involved in the development of chemoresistance in osteosarcoma cells, suggesting that targeting of IMPDH2 by RNAi or more effective pharmacological inhibitors in combination with chemotherapy might be a promising means of overcoming chemoresistance in osteosarcomas with high IMPDH2 expression.

Citing Articles

Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer.

da Silva Fernandes T, Gillard B, Dai T, Martin J, Chaudhry K, Dugas S Sci Rep. 2025; 15(1):1061.

PMID: 39774345 PMC: 11707137. DOI: 10.1038/s41598-024-85094-5.

Growth Transformation of B Cells by Epstein-Barr Virus Requires Induction and Nucleolar Hypertrophy.

Sugimoto A, Watanabe T, Matsuoka K, Okuno Y, Yanagi Y, Narita Y Microbiol Spectr. 2023; 11(4):e0044023.

PMID: 37409959 PMC: 10433962. DOI: 10.1128/spectrum.00440-23.

The emerging relationship between metabolism and DNA repair.

Cucchi D, Gibson A, Martin S Cell Cycle. 2021; 20(10):943-959.

PMID: 33874857 PMC: 8172156. DOI: 10.1080/15384101.2021.1912889.

Metabolic Compartmentalization at the Leading Edge of Metastatic Cancer Cells.

Wolfe K, Kamata R, Coutinho K, Inoue T, Sasaki A Front Oncol. 2020; 10:554272.

PMID: 33224873 PMC: 7667250. DOI: 10.3389/fonc.2020.554272.

A Correlation Between Intracellular Zinc Content and Osteosarcoma.

Meshkini A Biol Trace Elem Res. 2020; 199(9):3222-3231.

PMID: 33150482 DOI: 10.1007/s12011-020-02466-4.

References

Fellenberg J, Dechant M, Ewerbeck V, Mau H . Identification of drug-regulated genes in osteosarcoma cells. Int J Cancer. 2003; 105(5):636-43. DOI: 10.1002/ijc.11135. View

Penuelas S, Noe V, Ciudad C . Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J. 2005; 272(3):696-710. DOI: 10.1111/j.1742-4658.2004.04504.x. View

Messina E, Gazzaniga P, Micheli V, Guaglianone M, Barbato S, Morrone S . Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer. 2004; 108(6):812-7. DOI: 10.1002/ijc.11642. View

Olah E, Natsumeda Y, Ikegami T, Kote Z, Horanyi M, Szelenyi J . Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells. Proc Natl Acad Sci U S A. 1988; 85(17):6533-7. PMC: 282007. DOI: 10.1073/pnas.85.17.6533. View

Provisor A, Ettinger L, Nachman J, Krailo M, Makley J, Yunis E . Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15(1):76-84. DOI: 10.1200/JCO.1997.15.1.76. View

Khanna N, Jayaram H, Singh N . Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci. 2004; 75(2):179-90. DOI: 10.1016/j.lfs.2003.11.026. View

Sidi Y, Panet C, Wasserman L, Cyjon A, Novogrodsky A, Nordenberg J . Growth inhibition and induction of phenotypic alterations in MCF-7 breast cancer cells by an IMP dehydrogenase inhibitor. Br J Cancer. 1988; 58(1):61-3. PMC: 2246497. DOI: 10.1038/bjc.1988.162. View

Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G . Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 1991; 51(15):3886-90. View

Zimmermann A, Gu J, Spychala J, Mitchell B . Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Adv Enzyme Regul. 1996; 36:75-84. DOI: 10.1016/0065-2571(95)00012-7. View

10.

Natsumeda Y, Carr S . Human type I and II IMP dehydrogenases as drug targets. Ann N Y Acad Sci. 1993; 696:88-93. DOI: 10.1111/j.1749-6632.1993.tb17144.x. View

11.

Jackson R, Weber G, MORRIS H . IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 1975; 256(5515):331-3. DOI: 10.1038/256331a0. View

12.

Chen L, Pankiewicz K . Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel. 2007; 10(4):403-12. View

13.

Tricot G, Jayaram H, Lapis E, Natsumeda Y, Nichols C, Kneebone P . Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. Cancer Res. 1989; 49(13):3696-701. View

14.

RUSSELL W, SUTOW W, Martin R . Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977; 67(5):427-35. DOI: 10.1093/ajcp/67.5.427. View

15.

Ratcliffe A . Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases. Curr Opin Drug Discov Devel. 2006; 9(5):595-605. View

16.

Takebe N, Cheng X, Fandy T, Srivastava R, Wu S, Shankar S . IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006; 5(2):457-66. DOI: 10.1158/1535-7163.MCT-05-0340. View

17.

Goorin A, Shuster J, Baker A, Horowitz M, Meyer W, Link M . Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991; 9(4):600-5. DOI: 10.1200/JCO.1991.9.4.600. View

18.

Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A . Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007; 20(10):1085-94. DOI: 10.1038/modpathol.3800937. View

19.

Jayaram H, Cooney D, Grusch M, Krupitza G . Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem. 1999; 6(7):561-74. View

20.

Yalowitz J, Jayaram H . Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 2000; 20(4):2329-38. View